Glow Peptide: Dosage Chart, Benefits and the Full Protocol

The glow peptide is a three-compound blend sold in one lyophilised vial: GHK-Cu, BPC-157 and TB-500. The format almost every vendor ships in September 2026 is a 70 mg vial holding 50 mg of GHK-Cu and 10 mg each of the other two, a fixed 5:1:1 ratio by mass. That is where the search term "glow 70 peptide" comes from, and it is the number every piece of arithmetic on this page is built on.

Dosing a blend is not the same as dosing three peptides. The vial is labelled by total mass, a dose is quoted in milligrams of the whole mixture, and the amount of each peptide in a draw has to be worked back out of the ratio. Get that wrong and a "2 mg dose" of GLOW turns out to be 1.43 mg of GHK-Cu and 286 mcg each of BPC-157 and TB-500, which is a different protocol from the one the researcher thought they were running.

Below: the dosage chart at three reconstitution volumes, the frequency and cycle length most often reported, what each component contributes, what is documented on the before and after question, side effects, and what the vendors sell. The four-peptide version of the same blend is on the KLOW stack page, and the two are compared on Glow vs Klow.

Glow Peptide Dosage Chart

Start here. The table gives every combination of reconstitution volume and draw size that appears in circulation, with the per-component split worked out. A standard U-100 insulin syringe is 100 units to 1 mL, so units are simply the volume in millilitres multiplied by 100.

The row that matters most is the 3 mL, 10 unit line. That draw, 2.33 mg of blend, is the dose reported more than any other, and the reason is arithmetic rather than biology: 2.33 mg a day for thirty days is exactly 70 mg, so one vial is one month and the schedule falls out of the vial size. The dose was set by packaging, not by a dose response study.

Notice also that ten units at 2 mL, fifteen units at 3 mL and twenty units at 4 mL all deliver the same 3.5 mg of blend. Adding bacteriostatic water never changes how much peptide ends up in the syringe; it changes how far apart the marks are. That is the whole argument for the dilute options.

The Protocol and Cycle Length

There is no published dosing study for GLOW, so what follows is the schedule most often reported and reproduced across the charts in circulation, written against the 70 mg vial reconstituted with 3 mL. It is a description of practice.

The cycle reported for GLOW is shorter than the one reported for KLOW: roughly four weeks on and two to four weeks off, against eight to twelve on for the four-peptide blend. Part of that is again packaging, because one GLOW vial at the standard draw is thirty days, so the vial ends and the cycle ends with it.

The other reason to keep a break is copper. GHK-Cu is roughly 16 percent copper by mass, so the 1.67 mg of GHK-Cu in a standard draw carries about 0.27 mg of copper, delivered subcutaneously rather than through the gut. For scale, the adult dietary reference intake for copper is 0.9 mg a day. That is a modest fraction, but injected copper skips the intestinal regulation the dietary figure assumes, which is the argument for not running the blend continuously. The GHK-Cu injection dosage page works the copper arithmetic through in full.

How the blend compares to running the three separately

This is the question the ratio forces, and it is worth doing the numbers rather than assuming the blend matches single-compound practice.

So a standard GLOW draw is a normal GHK-Cu amount, a low-normal BPC-157 amount and a TB-500 amount closer to maintenance than loading. That is the trade every fixed-ratio blend makes: one injection instead of three, at the cost of any control over the proportions. A researcher whose actual interest is tendon or ligament work is better served by BPC-157 and TB-500 separately, or by the Wolverine stack. A researcher whose interest is skin is getting what they came for.

Reconstitution, Colour and Syringe Units

GLOW is reconstituted like any lyophilised vial: bacteriostatic water down the side of the glass rather than onto the powder, swirl, never shake. The bacteriostatic water guide and the reconstitution guide cover the handling and how long a mixed vial keeps refrigerated.

Two things are specific to this blend. The first is colour: GHK-Cu is 71 percent of the mass, copper(II) complexes are blue to violet in solution, and so a correctly reconstituted GLOW vial is blue. A clear solution from a vial sold as GLOW is worth a question to the vendor. Cloudiness or visible particles mean the vial is not usable.

The second is the sting. GHK-Cu is widely reported to burn on injection in a way most research peptides do not, with no published explanation. The responses in circulation are to reconstitute with more water and to inject slowly. Both are anecdote, and both are the reason the 4 mL row exists.

The arithmetic: concentration is vial milligrams divided by millilitres of water, volume per dose is dose divided by concentration, and units are that volume multiplied by 100. A 70 mg vial in 3 mL is 23.33 mg/mL, so 2.33 mg is 0.0999 mL, or 10 units. Vendors occasionally ship 75 mg vials under the same name, in which case none of the rows above apply; put the vendor's stated milligrams into the GLOW calculator instead.

Glow Peptide Benefits, Component by Component

No published study has tested GHK-Cu, BPC-157 and TB-500 together, so there is no evidence for the glow blend as such. What exists is evidence for three separate compounds, weighted here by how much of the vial each one occupies.

GHK-Cu. The compound the blend is built around, and the only one with controlled human data. A multicentre randomised trial in diabetic neuropathic foot ulcers reported a median 98.5 percent closure with a GHK-Cu gel against 60.8 percent for vehicle. A second randomised trial, in skin after CO2 laser resurfacing, found no objective difference in wrinkles or skin quality at twelve weeks; only patient satisfaction was higher. Both are topical. There is no published human trial of injected GHK-Cu alone, which is why the 1 to 2 mg injection figure is a convention. See the GHK-Cu guide and topical GHK-Cu.

BPC-157. The rodent work is extensive and consistent across tendon, ligament, muscle and gut models, and there is essentially nothing in humans. On regulatory status: FDA removed BPC-157 from Category 2 in April 2026 and it remains under Pharmacy Compounding Advisory Committee review; it is not currently compoundable. Injectable GHK-Cu was moved out of Category 2 in the same action and is scheduled for a later committee review. The BPC-157 guide covers the animal data.

TB-500. The name is doing more work than the molecule. Thymosin beta-4, the full 43-amino-acid protein, has been through human phase 2 trials in wound and cardiac settings. TB-500 as sold to researchers is a fragment, and published data on the fragment specifically is animal and in vitro. That distinction is the most common misreading of the evidence for this blend. See the TB-500 guide and TB-500 vs BPC-157.

The composite picture: one compound with human data in the wrong route, one with a deep animal literature and no human trials, and one whose human data belongs to a different molecule. At 71 percent of the vial by mass, GHK-Cu is what a researcher is mostly buying.

Glow Peptide Before and After: What Is Actually Documented

"Glow peptide before and after" is one of the highest-volume searches around this blend, and it is almost entirely served by vendor galleries and social posts. Worth separating what exists.

Documented in controlled human research, for GHK-Cu topically: faster wound closure in diabetic foot ulcers. That is a real result with a real control group, and it is about wounds, not appearance. In the one controlled trial with cosmetic endpoints, blinded evaluators found no objective difference at twelve weeks. Those two results are the entire controlled human record for the main component, and they point in different directions.

Not documented: any before and after for the blend as sold. No imaging study, no blinded evaluation, no standardised photography and no control arm exists for GLOW. Every photo pair in circulation is uncontrolled, self-selected and shot under whatever light the person had, and a photograph is easy to change through lighting, hydration, tan and camera processing without anything underneath changing.

What the component research does establish is a timescale, which is the useful part. Collagen remodelling is measured in months, and the controlled trial that produced a positive result ran twelve weeks before reading its endpoint. Reported observations cluster at four to eight weeks for skin texture and longer for hair, because a follicle cycle runs at its own pace. A researcher evaluating a four-week cycle at day ten is reading noise.

Side Effects Reported With the Components

There is no safety study of the blend, so the reported profile is the sum of the components, weighted towards GHK-Cu because that is most of the vial.

The unknowns matter more than that list: none of the three has published long-term human safety data by injection. Copper is the one caution that is not anecdotal, and anyone with Wilson's disease or another copper handling disorder should not be adding copper by any route. See the GHK-Cu side effects page and the general side effects guide.

Where to Buy the Glow Peptide Online

Disclosure. Links in this section may earn the Bureau a commission at no additional cost to the reader. The method is on the vendor scorecard page. Compositions and prices are as the vendor displayed them when the Bureau checked, and vendors change both.

The component route is the row most people skip. At those September prices it lands at essentially the same cost as a blend vial for the same 70 mg of the same three compounds, while leaving the ratio under the researcher's control. What it costs is convenience: three vials to reconstitute and store instead of one. The blend buys a single injection; it sells the ability to run BPC-157 at 500 mcg without also running 2.5 mg of GHK-Cu.

Two cautions. GLOW is not a specification: vendors ship it at 70 mg, 75 mg and occasionally other sizes, and only some itemise the split, so read the composition line before comparing prices. And a single purity figure on a blend COA is close to meaningless, because GHK-Cu chromatographs differently from the other two and copper content is not measured by a standard HPLC purity test at all. The testing guide explains what a blend COA can and cannot tell you.

Where the Arithmetic Goes Wrong

• Reading a blend dose as a single-compound dose. "2 mg of GLOW" is 1.43 mg of GHK-Cu and 286 mcg each of BPC-157 and TB-500. It is not 2 mg of anything.
• Assuming the vial is 70 mg. Vendors ship 75 mg and other sizes under the same name. Every row in the chart above changes if the vial does.
• Assuming a 5:1:1 split the vendor has not stated. If it is not on the page or the COA, the ratio is an assumption.
• Thinking more water means a bigger dose. It means more syringe units for the same milligrams, which is easier to measure and nothing else.
• Treating the TB-500 content as a loading dose. A daily GLOW draw delivers about 2.3 mg of TB-500 a week, against 4 to 10 mg a week in single-compound loading protocols.
• Judging a cycle on photographs at two weeks. The one controlled human trial with a cosmetic endpoint read it at twelve weeks, and found no objective difference.

Key Takeaways

• GLOW is 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 in a 70 mg vial, a fixed 5:1:1 ratio
• The most reported dose is 10 units daily from a 3 mL reconstitution, which is 2.33 mg of blend and 1.67 / 0.33 / 0.33 mg of the three components
• Thirty of those draws is exactly one vial, which is where the four-week cycle came from
• 2 mL is 35 mg/mL, 3 mL is 23.33 mg/mL, 4 mL is 17.5 mg/mL; more water changes units, not milligrams
• The blend delivers a normal GHK-Cu amount, a low-normal BPC-157 amount and a maintenance-level TB-500 amount
• No study has tested the three together, and GHK-Cu's controlled human data is topical
• The solution is blue because of the copper, and the injection sting is the most common complaint
• Buying the three separately costs about the same and keeps the ratio under your control

Frequently Asked Questions

What is the glow peptide?

GLOW is a three-peptide blend sold in a single lyophilised vial: GHK-Cu, BPC-157 and TB-500. The standard September 2026 format is a 70 mg vial holding 50 mg of GHK-Cu and 10 mg each of BPC-157 and TB-500, a fixed 5:1:1 ratio by mass. Because the ratio is fixed in the powder, a researcher cannot change one component without changing all three. GLOW is the same blend as KLOW minus the 10 mg of KPV, which is why the two are so often confused. All three compounds are sold for research use and none of them is an approved medicine.

What is the glow peptide dosage?

The most widely reported schedule is 10 units a day from a 70 mg vial reconstituted with 3 mL of bacteriostatic water. That concentration is 23.33 mg per mL, so a 10 unit draw is 0.1 mL and 2.33 mg of total blend, which splits into roughly 1.67 mg of GHK-Cu and 0.33 mg each of BPC-157 and TB-500. Thirty of those draws consume exactly one 70 mg vial, which is why the reported cycle is about four weeks on followed by two to four weeks off. The same 2.33 mg is about 7 units if the vial is reconstituted with 2 mL instead. These figures describe what is reported in practice, not a validated dosing study.

How much bacteriostatic water goes into a 70 mg GLOW vial?

Three volumes cover almost every protocol in circulation. 2 mL gives 35 mg per mL, so 10 units is 3.5 mg of blend. 3 mL gives 23.33 mg per mL, so 10 units is 2.33 mg, and this is the dilution most published charts are written against. 4 mL gives 17.5 mg per mL, so 10 units is 1.75 mg. More water does not change how much compound a researcher ends up delivering, it changes how many syringe units that amount reads as, and a larger number of units is easier to measure accurately. A more dilute solution is also the usual answer to the stinging that GHK-Cu is known for.

What does each peptide in the glow blend contribute?

GHK-Cu is 50 of the 70 mg, so it dominates the blend by mass and is the reason the reconstituted solution is blue. It is a copper-binding tripeptide with a large preclinical literature on collagen synthesis and skin remodelling, and two controlled human trials, both of them topical. BPC-157 is 10 mg and carries a large rodent literature on tendon, ligament and gut tissue with no published human trials. TB-500 is 10 mg and is sold as a fragment of thymosin beta-4, with animal and cell data behind the fragment itself. No published study has tested the three together, so any effect attributed to the blend is an inference from single-compound work.

How long does the glow peptide take to show a result?

Nothing in the literature answers this for the blend, because the blend has never been studied. What the component research sets is a floor on how fast the underlying biology moves. Collagen remodelling in the GHK-Cu work is measured in months rather than weeks, and the controlled topical trial that showed an effect ran twelve weeks. Reported observations in practice cluster at four to eight weeks for skin texture and considerably longer for anything involving hair, because a follicle cycle sets that pace. A researcher judging a four-week cycle at day ten is reading noise.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.